Recruiting
Phase 1

STK-012

Sponsor:

Synthekine

Code:

NCT05098132

Conditions

Advanced Solid Tumor

Non Small Cell Lung Cancer

Head and Neck Squamous Cell Carcinoma

Malignant Melanoma

Renal Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

STK-012

pembrolizumab

pemetrexed

carboplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by Synthekine on 2025-08-07.